Trials / Completed
CompletedNCT01518387
Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients
Phase III Open Study of BAY 77 1931 (Lanthanum Carbonate) in Patients With Hyperphosphatemia Undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (lanthanum carbonate) in patients with hyperphosphatemia undergoing continuous ambulatory peritoneal dialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanthanum Carbonate (BAY77-1931) |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2006-07-01
- Completion
- 2006-07-01
- First posted
- 2012-01-26
- Last updated
- 2016-03-14
Locations
11 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01518387. Inclusion in this directory is not an endorsement.